SUBSCRIBE
SUBSCRIBE

Postmarket research

Drug Development
Ohio State University: Feline Virus, Antiviral Drug Studied To Understand Drug Resistance
November 28, 2007
 · 
1 min read
Drug Development
Controlling Cholera with Oral Vaccines, Fred Hutchinson Cancer Research Center Study
November 27, 2007
 · 
1 min read
Drug Development
Alzheimer Drugs Don’t Delay Dementia Onset: Study
November 27, 2007
 · 
1 min read
Drug Development
Increased Lifespan Link to Depression Drug
November 26, 2007
 · 
1 min read
Drug Development
Carbon Monoxide Counteracts One Side-Effect of an Anti-Cancer Drug
November 26, 2007
 · 
1 min read
Drug Development
Post-Exposure HIV Drugs Won’t Boost Risky Behavior
November 26, 2007
 · 
1 min read
Drug Development
Cancer Drug Works by Overactivating Cancer Gene, University of Michigan Health System Study
November 20, 2007
 · 
1 min read
Drug Development
Study Shows Suppressing Herpes Virus May Reduce Infectiousness of HIV
November 15, 2007
 · 
1 min read
Drug Development
Possible Link Found Between BRCA1 and Antiestrogen Drug Resistance
November 14, 2007
 · 
1 min read
Drug Development
Vaccines Cut Disease Deaths by 99 Percent: Study
November 14, 2007
 · 
1 min read
Load More
PRESS RELEASES
Drug Development
Exelixis, Inc.’ Cabozantinib Phase 2 Data Demonstrate Reduction in Bone Pain and Narcotic Analgesic Use in Patients with Previously Treated mCRPC
November 14, 2011
 · 
9 min read
Drug Development
Exelixis, Inc. Release: Preliminary Data Demonstrate that 40 mg Daily Dose of Cabozantinib Yields a High Rate of Bone Scan Response in mCRPC
November 14, 2011
 · 
10 min read
Drug Development
The Medicines Company Release: German Researchers Reaffirm Utility of Angiomax(R)/Angiox(R) (Bivalirudin) in High Risk PCI Patients
November 14, 2011
 · 
5 min read
Drug Development
Bristol-Myers Squibb Company, Pfizer Inc. Clot Drug Fails to Help Ill Patients
November 14, 2011
 · 
1 min read
Drug Development
Questcor Pharmaceuticals, Inc. (Headquarters) Release: New Research Suggests That Acthar Reduces Proteinuria in Idiopathic Membranous Nephropathy In Part Through Suppression of Anti-PLA2R Antibodies
November 11, 2011
 · 
4 min read
Drug Development
Abbott Laboratories’s Cholesterol Drug May Not Lower Heart Risks
November 10, 2011
 · 
1 min read
Drug Development
Synta Pharmaceuticals Announces Results Show Ganetespib Sensitizes Rectal Cancer Cells to Chemoradiotherapy
November 10, 2011
 · 
1 min read
Drug Development
Pamlab LLC Release: Data Affirms Long Term Benefit of Adding L-methylfolate to An Antidepressant — Genetic Markers Identified, BMI Possible Predictor of Efficacy
November 9, 2011
 · 
1 min read
Drug Development
Studies Show GlaxoSmithKline’s HPV Vaccine Fights Cervical Cancer
November 9, 2011
 · 
1 min read
Drug Development
Alkermes plc Release: New Long-Term Data on VIVITROL® Showed Sustained Efficacy and Safety over 18 Months of Treatment
November 9, 2011
 · 
1 min read
Drug Development
Bristol-Myers Squibb Company Release: Phase IIIb Comparison of BARACLUDE® (entecavir) Monotherapy Versus BARACLUDE Plus Tenofovir Combination Shows No Statistical Difference Between Study Arms
November 8, 2011
 · 
1 min read
Drug Development
Pfizer Inc.'s Toviaz Top-Line Primary Endpoint Results Positive in Overactive Bladder Study of Nocturnal Urinary Urgency
November 8, 2011
 · 
3 min read
Drug Development
Pfizer Inc. Release: Toviaz Top-Line Primary Endpoint Results Positive In Overactive Bladder Study of Nocturnal Urinary Urgency
November 8, 2011
 · 
1 min read
Drug Development
Amgen Release; Treatment With Enbrel(R) (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease
November 7, 2011
 · 
16 min read
Drug Development
Fibrocell Science, Inc. Release: Studies Show LAVIV™ (azficel-T) Effectively Improves the Appearance of Smile Line Wrinkles
November 7, 2011
 · 
1 min read
Drug Development
Boehringer Ingelheim Corporation Release: Hepatitis C: Interferon-free Combination of BI 201335 Plus BI 207127 and ribavirin Shows up to 76% of Patients Achieve a Virological Response at Week 12, and 59% Achieve SVR12 with 16 Weeks Treatment 1
November 7, 2011
 · 
1 min read
Drug Development
Iroko Pharmaceuticals Release: Pain Medicines in Novel Formulations Show Potential for Relief at Lower Doses
November 7, 2011
 · 
1 min read
Drug Development
Fibrocell Science, Inc. Release: LAVIV™ (azficel-T) Demonstrates Improvement in Acne Scarring
November 3, 2011
 · 
1 min read
Drug Development
Auxilium Pharmaceuticals Release: TRiUS Data Suggests That Testim(R) Significantly Improved Sexual Function in Hypogonadal Men
November 3, 2011
 · 
7 min read
Drug Development
Vertex Pharmaceuticals Incorporated Release: Phase 3 Study of KALYDECO™ (ivacaftor) in Children Ages 6 to 11 with a Specific Type of Cystic Fibrosis Showed Significant Improvements in Lung Function and Other Measures of Disease Sustained Through 48 Weeks
November 3, 2011
 · 
1 min read
Load More